Tonix Pharmaceuticals Holding (TNXP) EBIT Margin (2023 - 2025)
Historic EBIT Margin for Tonix Pharmaceuticals Holding (TNXP) over the last 3 years, with Q3 2025 value amounting to 1005.08%.
- Tonix Pharmaceuticals Holding's EBIT Margin fell 4539100.0% to 1005.08% in Q3 2025 from the same period last year, while for Sep 2025 it was 969.97%, marking a year-over-year increase of 2836900.0%. This contributed to the annual value of 1354.28% for FY2024, which is 1696600.0% up from last year.
- Latest data reveals that Tonix Pharmaceuticals Holding reported EBIT Margin of 1005.08% as of Q3 2025, which was down 4539100.0% from 1416.22% recorded in Q2 2025.
- In the past 5 years, Tonix Pharmaceuticals Holding's EBIT Margin ranged from a high of 551.17% in Q3 2024 and a low of 3501.63% during Q2 2024
- Its 3-year average for EBIT Margin is 1143.86%, with a median of 860.23% in 2024.
- Examining YoY changes over the last 5 years, Tonix Pharmaceuticals Holding's EBIT Margin showed a top increase of 20854100bps in 2025 and a maximum decrease of -4539100bps in 2025.
- Tonix Pharmaceuticals Holding's EBIT Margin (Quarter) stood at 723.18% in 2023, then dropped by -20bps to 870.64% in 2024, then fell by -15bps to 1005.08% in 2025.
- Its EBIT Margin stands at 1005.08% for Q3 2025, versus 1416.22% for Q2 2025 and 660.93% for Q1 2025.